DexCom Q1 2024 Adj EPS $0.32 Beats $0.27 Estimate, Sales $921.000M Beat $909.238M Estimate
Portfolio Pulse from Benzinga Newsdesk
DexCom reported Q1 2024 adjusted EPS of $0.32, surpassing the $0.27 estimate, with sales of $921M also beating the $909.238M forecast. This represents a 24.21% increase in sales compared to the same period last year.
April 25, 2024 | 8:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
DexCom's Q1 2024 earnings and sales exceeded analyst expectations, with a significant year-over-year sales growth.
Beating both EPS and sales estimates, especially with a substantial year-over-year sales increase, typically leads to positive investor sentiment and could boost the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100